| Chronic Kidney Diseases
Renvela vs Xphozah
Side-by-side clinical, coverage, and cost comparison for chronic kidney diseases.Deep comparison between: Renvela vs Xphozah 10 Mg with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXphozah 10 Mg has a higher rate of injection site reactions vs Renvela based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xphozah 10 Mg but not Renvela, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Renvela
Xphozah 10 Mg
At A Glance
Oral
Three times daily with meals
Phosphate binder
Oral
Twice daily
NHE3 inhibitor
Indications
- Chronic Kidney Diseases
- Chronic Kidney Diseases
Dosing
Chronic Kidney Diseases (Adults) Starting dose 0.8-1.6 g orally three times daily with meals based on serum phosphorus level; titrate by 0.8 g per meal at two-week intervals to achieve target serum phosphorus.
Chronic Kidney Diseases (Pediatric, >=6 years) Starting dose 0.8-1.6 g three times daily with meals based on body surface area (BSA) category; titrate based on BSA category at two-week intervals for 6 weeks then every 4 weeks as needed.
Chronic Kidney Diseases 30 mg orally twice daily, taken just prior to the first and last meals of the day; monitor serum phosphorus and adjust dosage as needed for gastrointestinal tolerability.
Contraindications
- Bowel obstruction
- Known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or any excipient
- Age under 6 years due to risk of diarrhea and serious dehydration
- Known or suspected mechanical gastrointestinal obstruction
Adverse Reactions
Most common (>5%) Vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, constipation
Postmarketing Hypersensitivity, pruritus, rash, abdominal pain, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, fecal impaction, ileus, intestinal obstruction, intestinal perforation
Most common (>=5%) Diarrhea (43-53% of patients)
Postmarketing Pruritis, rash, urticaria
Pharmacology
Sevelamer carbonate is a non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium, that binds phosphate in the gastrointestinal tract via ionic and hydrogen bonding, thereby decreasing phosphate absorption and lowering serum phosphorus concentrations.
NHE3 inhibitor; tenapanor is a locally acting inhibitor of sodium/hydrogen exchanger 3 (NHE3), an antiporter on the apical surface of intestinal epithelium, whose inhibition reduces sodium absorption and decreases phosphate absorption by reducing paracellular phosphate permeability.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Renvela
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (4/12) · Qty limit (9/12)
Xphozah 10 Mg
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Renvela
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Xphozah 10 Mg
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Renvela
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Xphozah 10 Mg
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Renvela.
No savings programs available for Xphozah 10 Mg.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RenvelaView full Renvela profile
Xphozah 10 MgView full Xphozah 10 Mg profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.